CRESCENT BIOPHARMA INC (CBIO) Fundamental Analysis & Valuation

NASDAQ:CBIO • KYG2545C1042

12.07 USD
+0.74 (+6.53%)
At close: Mar 6, 2026
12.07 USD
0 (0%)
After Hours: 3/6/2026, 8:04:35 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

CBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. While CBIO has a great health rating, there are worries on its profitability. CBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. CBIO Profitability Analysis

1.1 Basic Checks

  • CBIO had negative earnings in the past year.
  • In the past year CBIO has reported a negative cash flow from operations.
  • CBIO had negative earnings in each of the past 5 years.
  • In the past 5 years CBIO always reported negative operating cash flow.
CBIO Yearly Net Income VS EBIT VS OCF VS FCFCBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -26.16%, CBIO is doing good in the industry, outperforming 68.85% of the companies in the same industry.
  • The Return On Equity of CBIO (-29.57%) is better than 75.58% of its industry peers.
Industry RankSector Rank
ROA -26.16%
ROE -29.57%
ROIC N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
CBIO Yearly ROA, ROE, ROICCBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • CBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBIO Yearly Profit, Operating, Gross MarginsCBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CBIO Health Analysis

2.1 Basic Checks

  • CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CBIO Yearly Shares OutstandingCBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CBIO Yearly Total Debt VS Total AssetsCBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • CBIO has an Altman-Z score of 10.14. This indicates that CBIO is financially healthy and has little risk of bankruptcy at the moment.
  • CBIO has a Altman-Z score of 10.14. This is amongst the best in the industry. CBIO outperforms 81.54% of its industry peers.
  • There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.14
ROIC/WACCN/A
WACC8.79%
CBIO Yearly LT Debt VS Equity VS FCFCBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 9.21 indicates that CBIO has no problem at all paying its short term obligations.
  • CBIO's Current ratio of 9.21 is fine compared to the rest of the industry. CBIO outperforms 78.27% of its industry peers.
  • A Quick Ratio of 9.21 indicates that CBIO has no problem at all paying its short term obligations.
  • CBIO has a better Quick ratio (9.21) than 78.27% of its industry peers.
Industry RankSector Rank
Current Ratio 9.21
Quick Ratio 9.21
CBIO Yearly Current Assets VS Current LiabilitesCBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CBIO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.09% over the past year.
  • CBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
  • Measured over the past years, CBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -90.05% on average per year.
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.04% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.93%
EPS Next 2Y33.54%
EPS Next 3Y24.08%
EPS Next 5Y14.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. CBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBIO Price Earnings VS Forward Price EarningsCBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBIO Per share dataCBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CBIO's earnings are expected to grow with 24.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.54%
EPS Next 3Y24.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CBIO Dividend Analysis

5.1 Amount

  • CBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CBIO Fundamentals: All Metrics, Ratios and Statistics

CRESCENT BIOPHARMA INC

NASDAQ:CBIO (3/6/2026, 8:04:35 PM)

After market: 12.07 0 (0%)

12.07

+0.74 (+6.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners85.88%
Inst Owner Change109.93%
Ins Owners0.99%
Ins Owner Change17.08%
Market Cap332.65M
Revenue(TTM)10.00K
Net Income(TTM)-41.18M
Analysts86.67
Price Target29.92 (147.89%)
Short Float %5.02%
Short Ratio7.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-76.33%
Min EPS beat(2)-174.23%
Max EPS beat(2)21.57%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.69%
PT rev (3m)15.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-61.18%
EPS NY rev (3m)-70.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 2.39
EV/EBITDA N/A
EPS(TTM)-58
EYN/A
EPS(NY)-12.58
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0
BVpS5.05
TBVpS5.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.16%
ROE -29.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1372.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.21
Quick Ratio 9.21
Altman-Z 10.14
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)26.82%
Cap/Depr(5y)22.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y98.93%
EPS Next 2Y33.54%
EPS Next 3Y24.08%
EPS Next 5Y14.04%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.93%
OCF growth 3YN/A
OCF growth 5YN/A

CRESCENT BIOPHARMA INC / CBIO FAQ

Can you provide the ChartMill fundamental rating for CRESCENT BIOPHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to CBIO.


What is the valuation status for CBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to CRESCENT BIOPHARMA INC (CBIO). This can be considered as Overvalued.


Can you provide the profitability details for CRESCENT BIOPHARMA INC?

CRESCENT BIOPHARMA INC (CBIO) has a profitability rating of 1 / 10.


Is the dividend of CRESCENT BIOPHARMA INC sustainable?

The dividend rating of CRESCENT BIOPHARMA INC (CBIO) is 0 / 10 and the dividend payout ratio is 0%.